Tags

Type your tag names separated by a space and hit enter

[Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance].
Enferm Infecc Microbiol Clin. 2004 Jun-Jul; 22(6):323-7.EI

Abstract

INTRODUCTION

Antimicrobial resistance among strains of Streptococcus pneumoniae, Haemophilus influenza, and Streptococcus pyogenes has limited the usefulness of conventional agents for the treatment of some infectious diseases related with these microorganisms. There is thus a clear need for new antimicrobial agents active against these resistant strains.

OBJECTIVES

To assess the in vitro susceptibility to telithromycin and other oral antimicrobial agents of 307 strains of S. pneumoniae, H. influenzae, and S. pyogenes with acquired mechanisms of resistance to macrolides and/or beta-lactams.

METHODS

Antimicrobial susceptibility testing was performed by the agar dilution method, and results were preferentially evaluated according to National Committee for Clinical Laboratory Standards (NCCLS) guidelines.

RESULTS

The activity of telithromycin against erythromycin-resistant S. pneumoniae was excellent. All the strains were inhibited with 2 mg/l, regardless of the mechanism of macrolide resistance exhibited. Telithromycin was slightly more active than the tested macrolides in beta-lactamase-producing H. influenzae strains, with a MIC90 of 2 mg/l. Telithromycin also demonstrated potent activity against macrolide-resistant S. pyogenes. The MIC of telithromycin was > 4 mg/l for only one out of the 202 tested strains.

CONCLUSIONS

Telithromycin is a very promising therapeutic option against bacterial pathogens of the respiratory tract, including strains that have developed mechanisms of resistance to macrolides and/or beta-lactams.

Authors+Show Affiliations

Servicio de Microbiología, Hospital de Móstoles, Instituto Madrileño de la Salud, Móstoles, Madrid, Spain. jlgarces@microb.netNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

spa

PubMed ID

15228898

Citation

Gómez-Garcés, José Luis, et al. "[Activity of Telithromycin and Other Oral Antibiotics Against Respiratory Tract Pathogens With Acquired Mechanisms of Resistance]." Enfermedades Infecciosas Y Microbiologia Clinica, vol. 22, no. 6, 2004, pp. 323-7.
Gómez-Garcés JL, Alós JI, Hernáiz C, et al. [Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance]. Enferm Infecc Microbiol Clin. 2004;22(6):323-7.
Gómez-Garcés, J. L., Alós, J. I., Hernáiz, C., & Gómez, C. (2004). [Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance]. Enfermedades Infecciosas Y Microbiologia Clinica, 22(6), 323-7.
Gómez-Garcés JL, et al. [Activity of Telithromycin and Other Oral Antibiotics Against Respiratory Tract Pathogens With Acquired Mechanisms of Resistance]. Enferm Infecc Microbiol Clin. 2004 Jun-Jul;22(6):323-7. PubMed PMID: 15228898.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance]. AU - Gómez-Garcés,José Luis, AU - Alós,Juan Ignacio, AU - Hernáiz,Carmen, AU - Gómez,Carmen, PY - 2004/7/2/pubmed PY - 2004/10/6/medline PY - 2004/7/2/entrez SP - 323 EP - 7 JF - Enfermedades infecciosas y microbiologia clinica JO - Enferm Infecc Microbiol Clin VL - 22 IS - 6 N2 - INTRODUCTION: Antimicrobial resistance among strains of Streptococcus pneumoniae, Haemophilus influenza, and Streptococcus pyogenes has limited the usefulness of conventional agents for the treatment of some infectious diseases related with these microorganisms. There is thus a clear need for new antimicrobial agents active against these resistant strains. OBJECTIVES: To assess the in vitro susceptibility to telithromycin and other oral antimicrobial agents of 307 strains of S. pneumoniae, H. influenzae, and S. pyogenes with acquired mechanisms of resistance to macrolides and/or beta-lactams. METHODS: Antimicrobial susceptibility testing was performed by the agar dilution method, and results were preferentially evaluated according to National Committee for Clinical Laboratory Standards (NCCLS) guidelines. RESULTS: The activity of telithromycin against erythromycin-resistant S. pneumoniae was excellent. All the strains were inhibited with 2 mg/l, regardless of the mechanism of macrolide resistance exhibited. Telithromycin was slightly more active than the tested macrolides in beta-lactamase-producing H. influenzae strains, with a MIC90 of 2 mg/l. Telithromycin also demonstrated potent activity against macrolide-resistant S. pyogenes. The MIC of telithromycin was > 4 mg/l for only one out of the 202 tested strains. CONCLUSIONS: Telithromycin is a very promising therapeutic option against bacterial pathogens of the respiratory tract, including strains that have developed mechanisms of resistance to macrolides and/or beta-lactams. SN - 0213-005X UR - https://www.unboundmedicine.com/medline/citation/15228898/[Activity_of_telithromycin_and_other_oral_antibiotics_against_respiratory_tract_pathogens_with_acquired_mechanisms_of_resistance]_ DB - PRIME DP - Unbound Medicine ER -